Aspira Women’s Health Announces Late-Breaking Poster Presentation at the Upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI)
12 Fevereiro 2024 - 10:00AM
Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a
bio-analytical based women’s health company focused on the
development of gynecologic disease diagnostic tools, today
announced a late-breaking poster presentation at the upcoming 71st
Annual Scientific Meeting for the Society for Reproductive
Investigation (SRI) to be held in Vancouver, Canada on March 12-16,
2024.
“Endometriomas are among the most common forms of endometriosis,
impacting millions of women. The presentation of data that is
foundational to our EndoCheckSM offering at this distinguished
conference is a major milestone for our plan to launch the first
noninvasive diagnostic test for this debilitating disease,” said
Nicole Sandford, Chief Executive Officer of Aspira.
Details of the poster presentation are as follows:
Poster Title: |
A
Protein Biomarker Test and Artificial Intelligence-Based Algorithm
for Ovarian Endometriosis |
Author: |
Todd Pappas, Ph.D., Vice
President of R&D at Aspira |
Abstract #: |
2066 |
Poster #: |
LB-F-04 |
Date: |
March 15, 2024 |
Time: |
9:00 – 10:00 am PST / 12:00 –1:00
pm EST |
Session: |
Late Breaking |
|
|
The abstract was co-authored by Aspira’s Research and
Development team and the Oxford Endometriosis Care and Research
(CaRe) Centre, a collaboration between Oxford University Hospitals
and the Nuffield Department of Women's Reproductive Health of the
University of Oxford. The poster will be available on the Company’s
investor relations website after it is presented at the
conference.
SRI, established in 1953, is an international society with over
900 members representing 35 countries. SRI strives to advance
reproductive health for all through outstanding basic,
translational, and clinical science; training and mentoring future
generations of investigators; and by promoting excellence in
reproductive sciences globally (www.sri-online.org).
About Aspira Women’s Health Inc. Aspira Women’s
Health Inc. is dedicated to the discovery, development, and
commercialization of noninvasive, AI-powered tests to aid in the
diagnosis of gynecologic diseases.
OvaWatchSM and Ova1Plus® are offered to clinicians as
OvaSuiteSM. Together, they provide the only comprehensive portfolio
of blood tests to aid in the detection of ovarian cancer for the
1.2+ million American women diagnosed with an adnexal mass each
year. OvaWatch provides a negative predictive value of 99% and is
used to assess ovarian cancer risk for women where initial clinical
assessment indicates the mass is indeterminate or benign, and thus
surgery may be premature or unnecessary. Ova1Plus is comprised of
two FDA-cleared tests, Ova1® and Overa®, to assess the risk of
ovarian malignancy in women planned for surgery.
Our in-development test pipeline is designed to expand our
ovarian cancer portfolio and addresses the tremendous need for
noninvasive diagnostics for endometriosis, a debilitating disease
that impacts millions of women worldwide. In ovarian cancer, our
OvaMDxSM risk assessment is designed to combine microRNA and
protein biomarkers with patient data to further enhance the
sensitivity and specificity of our current tests. In endometriosis,
EndoCheckSM is the first-ever noninvasive test designed to identify
endometriomas, one of the most commonly occurring forms of
endometriosis. The EndoMDxSM test is designed to combine microRNA
and protein biomarkers with patient data to identify all
endometriosis.
Forward-Looking Statements This press release
may contain forward-looking statements that are made pursuant to
the safe harbor provisions of the federal securities laws,
including those relating to the timing and completion of any
products in the pipeline development and other statement that are
predictive in nature. Actual results could differ materially from
those discussed due to known and unknown risks, uncertainties, and
other factors. These forward-looking statements generally can be
identified by the use of words such as “designed to,” “expect,”
“plan,” “anticipate,” “could,” “may,” “intend,” “will,” “continue,”
“future,” other words of similar meaning and the use of future
dates. Forward-looking statements in this press release and other
factors that may cause such differences include the satisfaction of
customary closing conditions related to the offering and the
expected timing of the closing of the offering. These and
additional risks and uncertainties are described more fully in the
company’s filings with the SEC, including those factors identified
as “risk factors” in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q. We are providing this
information as of the date of this press release and do not
undertake any obligation to update any forward-looking statements
contained in this document as a result of new information, future
events or otherwise, except as required by law.
Investor Relations Contact:Torsten Hombeck,
Ph.D.Chief Financial OfficerAspira Women’s
HealthInvestors@aspirawh.com
Aspira Womans Health (NASDAQ:AWH)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Aspira Womans Health (NASDAQ:AWH)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024